Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

OncoImmunology

Volumn 6, Issue 5, 2017, Pages

  Terabe, Masaki ^a   Robertson, Faith C ^a   Clark, Katharine ^a   De Ravin, Emma ^a   Bloom, Anja ^a   Venzon, David J ^a   Kato, Shingo ^a   Mirza, Amer ^b   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b XOMA Corporation   (United States)

Author keywords

Cancer vaccine; NKT; PD 1; PD L1; TGF beta

Indexed keywords

1D 11; CANCER VACCINE; CD11B ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; RECEPTOR BLOCKING AGENT; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; XPA 068; XPA 089;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LUNG METASTASIS; LYMPH NODE CELL; MALIGNANT NEOPLASM; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 85019254632     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1308616     Document Type: Article

References (34)

1. Lebman DA, Lee FD, Coffman RL. Mechanism for transforming growth factor beta and IL-2 enhancement of IgA expression in lipopolysaccharide-stimulated B cell cultures. J Immunol 1990; 144:952-9; PMID:2295822
2. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35; PMID:18167337; https://doi.org/10.1016/j.ccr.2007.12.004
3. Li MO, Flavell RA. TGF-beta:a master of all T cell trades. Cell 2008; 134:392-404; PMID:18692464; https://doi.org/10.1016/j.cell.2008.07.025
4. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16648838; https://doi.org/10.1038/nature04753
5. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194:629-44; PMID:11535631; https://doi.org/10.1084/jem.194.5.629
6. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007; 13:6247-51; PMID:17975134; https://doi.org/10.1158/1078-0432.CCR-07-1654
7. Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW. TGF-beta3 and cancer:a review. Cytokine Growth Factor Rev 2009; 20:305-17; PMID:19656717; https://doi.org/10.1016/j.cytogfr.2009.07.002
8. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol 1998; 160:1589-97; PMID:9247573; https://doi.org/10.1002/eji.1830270709
9. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Euro J Immunol 1997; 27:1648-56; PMID:9247573; https://doi.org/10.1002/eji.1830270709
10. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991-9; PMID:22961052; https://doi.org/10.1038/ni.2416
11. Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, Komai T, Shoda H, Miyazaki J, Fujio K, et al. TGF-beta3-expressing CD4+CD25(−)LAG3+ regulatory T cells control humoral immune responses. Nat Commun 2015; 6:6329; PMID:25695838; https://doi.org/10.1038/ncomms7329
12. Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM. Berzofsky JA. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer 2009; 126:1666-74; PMID:19830696; https://doi.org/10.1002/ijc.24961
13. Terabe M, Matsui S, Park J-M, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, et al. Transforming growth factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic t lymphocyte-mediated tumor immunosurveillance:abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-52; PMID:14657224; https://doi.org/10.1084/jem.20022227
14. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15:6560-9; PMID:19861451; https://doi.org/10.1158/1078-0432.CCR-09-1066
15. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009; 15:6551-9; PMID:19861464; https://doi.org/10.1158/1078-0432.CCR-09-1067
16. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68:10247-56; PMID:19074893; https://doi.org/10.1158/0008-5472.CAN-08-1494
17. Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother 2015; 64(4):437-46; PMID:25579378; https://doi.org/10.1007/s00262-015-1653-0
18. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61:3698-703; PMID:11325841
19. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169:350-8; PMID:12077264; https://doi.org/10.4049/jimmunol.169.1.350
20. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171:5140-7; PMID:14607913; https://doi.org/10.4049/jimmunol.171.10.5140
21. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002; 195:617-24; PMID:11877484; https://doi.org/10.1084/jem.20011889
22. Osmond TL, Farrand KJ, Painter GF, Ruedl C, Petersen TR, Hermans IF. Activated NKT cells can condition different splenic dendritic cell subsets to respond more effectively to TLR engagement and enhance cross-priming. J Immunol 2015; 195:821-31; PMID:26078270; https://doi.org/10.4049/jimmunol.1401751
23. Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, et al. A Distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 2016; 166:1500-11 e9; PMID:27610572; https://doi.org/10.1016/j.cell.2016.08.052
24. Cohn A, Lahn MM, Williams KE, Cleverly AL, Pitou C, Kadam SK, Farmen MW, Desaiah D, Raju R, Conkling P, et al. A phase I dose-escalation study to a predefined dose of a transforming growth factor-beta1 monoclonal antibody (TbetaM1) in patients with metastatic cancer. Int J Oncol 2014; 45:2221-31; PMID:25270361; https://doi.org/10.3892/ijo.2014.2679
25. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. Phase I study of GC1008 (fresolimumab):a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PloS One 2014; 9:e90353; PMID:24618589; https://doi.org/10.1371/journal.pone.0090353
26. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 2008; 68:5432-8; PMID:18593946; https://doi.org/10.1158/0008-5472.CAN-07-6598
27. Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, Yue D, Chen X, Ping Y, Huang L, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages. Int J Cancer 2016; 139:2261-9; PMID:27459735; https://doi.org/10.1002/ijc.30289
28. Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, et al. TGF-beta1-mediated Smad3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov 2016; 6(12):1366-81; PMID:27683557; https://doi.org/10.1158/2159-8290.CD-15-1347
29. Rekik R, Belhadj Hmida N, Ben Hmid A, Zamali I, Kammoun N, Ben Ahmed M. PD-1 induction through TCR activation is partially regulated by endogenous TGF-beta. Cell Mol Immunol 2015; 12:648-9; PMID:25363526; https://doi.org/10.1038/cmi.2014.104
30. Baas M, Besancon A, Goncalves T, Valette F, Yagita H, Sawitzki B, Volk HD, Waeckel-Enée E, Rocha B, Chatenoud L, et al. TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 2016; 5:e08133; PMID:26824266; https://doi.org/10.7554/eLife.08133
31. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, Honjo T. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011; 186:2772-9; PMID:21263073; https://doi.org/10.4049/jimmunol.1003208
32. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-79; PMID:12874260; https://doi.org/10.1084/jem.20030324
33. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008; 101:277-348; PMID:19055947; https://doi.org/10.1084/jem.20030324
34. Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res 2017; 5:29-41; PMID:27923825; https://doi.org/10.1158/2326-6066.CIR-16-0114